BNTC Benitec Biopharma Limited

2.31
+0.04  (2%)
Previous Close 2.27
Open 2.22
Price To book 1.44
Market Cap 20.31M
Shares 8,791,000
Volume 40,826
Short Ratio 0.51
Av. Daily Volume 416,260

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced late February 2016 plans to discontinue development
TT-034
Hepatitis C

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals
  2. Rising Biotechs: Paratek Among Stocks Surging On Trial Results
  3. Here's Why Benitec Biopharma Stock Soared 79.7% Higher This Morning
  4. Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
  5. Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics
  6. Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million
  7. Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
  8. M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix
  9. Why Benitec More Than Doubled
  10. Benitec Biopharma makes significant progress in ocular program
  11. Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital
  12. Biotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care
  13. Benitec Stock Up on Orphan Drug Status for BB-301 in EU
  14. Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy
  15. Tuesday’s Top Biopharma Movers
  16. Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy
  17. Benitec in-licenses clinical program for head and neck cancer from NantWorks
  18. Benitec releases pivotal data in an in vivo hepatitis B model
  19. Benitec initiates a strategic engagement with NantVentures
  20. Benitec announces restructuring of Senior Executive team